MOUNTAIN VIEW, Calif.,
Nov. 3 /PRNewswire/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the
Company will participate in the following investor conferences in
November:
|
Credit Suisse 2010 Healthcare
Conference
|
|
|
Wednesday, November 10, at 4:30
p.m. ET / 2:30 p.m. MT in Phoenix
|
|
|
|
|
Lazard Capital Markets 7th
Annual Healthcare Conference
|
|
|
Tuesday, November 16, at 9:55
a.m. ET in New York
|
|
|
A live webcast of each event will be available on the Investor
Relations section of MAP Pharmaceuticals' website at
http://www.mappharma.com. A replay also will be available within 24
hours for seven days following the presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company
focused on developing and commercializing new therapies to address
undermet patient needs in neurology. The Company is developing
LEVADEX orally inhaled therapy for the potential treatment of
migraine and has reported positive results from the efficacy
portion of its Phase 3 trial of LEVADEX. In addition, MAP
Pharmaceuticals generates new pipeline opportunities by applying
its proprietary drug particle and inhalation technologies to
enhance the therapeutic benefits of proven drugs, while minimizing
risk by capitalizing on their known safety, efficacy and
commercialization history.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
|
CONTACTS:
|
|
|
Nicole Foderaro
|
|
|
WCG
|
|
|
(415) 946-1058
|
|
|
nfoderaro@wcgworld.com
|
|
|
SOURCE MAP Pharmaceuticals, Inc.
Copyright v. 3 PR Newswire